Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftazidime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.99 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | APEX1 | P27695 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceftazidime SCHEMBL36849 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL27816764 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10746412 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10746421 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10678530 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL36850 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL23175189 | 0.99 | TDP1 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL7666202 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL20603074 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL9664455 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294521-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | Cap Diagnostics, LLC, DBA Pathnostics (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230392185-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics | 2023-12-07 | — | — | US | disclosed |
| US-20230357818-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-20230357817-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-11746371-B2 | Methods for treating polymicrobial infections | CAP Diagnostics, LLC (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220315975-A1 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | BANK OF HOPE | 2022-10-06 | — | — | US | disclosed |
| WO-2022178142-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20210301315-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | BANK OF HOPE | 2021-09-30 | — | — | US | disclosed |
| US-11053532-B2 | Methods for treating polymicrobial infections | CAP Diagnostics, LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210172000-A1 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | BANK OF HOPE | 2021-06-10 | — | — | US | disclosed |
| EP-3166959-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 Jian, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016144856-A1 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | SYNTHETIC BIOLOGICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016007551-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 JIAN, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015100432-A2 | METHOD FOR PROPAGATING MICROORGANISMS WITHIN PLANT BIOREACTORS AND STABLY STORING MICROORGANISMS WITHIN AGRICULTURAL SEEDS | SYMBIOTA, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| EP-2437596-A1 | SKIN TREATMENT COMPOSITIONS | Ex-Tek, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2011084882-A2 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA | CONTRAFECT CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| US-7928129-B1 | Nanomolar β-lactamase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2010141711-A1 | SKIN TREATMENT COMPOSITIONS | EX-TEK, LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| US-20050004118-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | JILANI JAMAL A (JO) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004118-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | HCAR2, NONO, ALOX15 | NR1I2 55/4885ESR1 1025/4885PPARG 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.